A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A

Peyvandi, Flora; Mannuccio Mannucci, Pier; Garagiola, Isabella; El‐Beshlawy, Amal; Saleh Elalfy, Mohsen; Ramanan, Vijay; Eshghi, Peyman; Hanagavadi, Suresh; Varadarajan, Ramabadran; Karimi, Mehran; Manglani, Mamta; Ross, Cecil; Young, Guy; Seth, Tulika; Apte, Shashikant; Nayak, Dinesh; Santagostino, Elena; Elisa Mancuso, Maria; Sandoval Gonzalez, A.C.; Mahlangu, Johnny; Bonanad Boix, Santiago; Cerqueira, M.; P. Ewing, Nadia; Male, Christoph; Owaidah, Tarek; Soto Arellano, V.; L. Kobrinsky, Nathan; Majumdar, Suvankar; Garrido, Rosario; Sachdeva, Anupam; Simpson, Mindy; Thomas, Mathew; Zanon, Ezio; Antmen, Bülent; Kavaklı, Kaan; J. Manco‐Johnson, Marilyn; Martínez, Mònica; Marzouka, E.; Gabriella Mazzucconi, Maria; Neme, Daniela; Palomo Bravo, Ángeles; Paredes Aguilera, Rogelio; Prezotti, A.; Schmitt, Klaus; M. Wicklund, Brian; Zülfikar, Bülent; R. Rosendaal, Frits

doi:10.1056/nejmoa1516437

Public

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A

Published in New England Journal of Medicine • May 25, 2016

Authors:

Flora Peyvandi

Pier Mannuccio Mannucci

Isabella Garagiola

Abstract

BACKGROUND: The development of neutralizing anti-factor VIII alloantibodies (inhibitors) in patients with severe hemophilia A may depend on the concentrate used for replacement therapy. METHODS: We conducted a randomized trial to assess the incidence of factor VIII inhibitors among patients treated ...

Subject

Medicine

Titer

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!